What influences aromatase inhibitor continuation intention among breast cancer survivors?
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose: Aromatase inhibitors (AIs) are widely prescribed for postmenopausal women with breast cancer and are known to cause musculoskeletal pain. This study aimed to identify factors associated with AI continuation intention among breast cancer survivors (BCS). Methods: A cross-sectional survey was conducted on 123 BCS (stages I–III), who had been taking AIs for at least 6 weeks. Participants were recruited from a cancer center in Goyang, Korea, from September to November 2019. Descriptive statistics, Welch analysis of variance, Pearson correlation coefficients, and simple linear regression were used for the analysis. Results: Beliefs about endocrine therapy was a significant predictor of AI continuation intention (β=.66, p<.001). The majority of participants (87.0%) reported experiencing musculoskeletal pain since taking AIs and the score for the worst pain severity within 24 hours was 5.08±2.80 out of 10. Musculoskeletal pain, however, was not associated with AI continuation intention. Fear of cancer recurrence (FCR) was clinically significant (≥13) for 74.0% of the respondents (mean, 17.62±7.14). Musculoskeletal pain severity and pain interference were significantly associated with FCR (r=.21, p<.05; r=.35, p<.01, respectively). Pain interference was significantly associated with beliefs about endocrine therapy (r=–.18, p<.05). Conclusion: AI continuation intention can be modified by reinforcing patients’ beliefs about endocrine therapy. Musculoskeletal pain may have a negative effect on beliefs about endocrine therapy and increase FCR among BCS. Thus, awareness of musculoskeletal pain during AI therapy should be raised and further research is required to develop multidisciplinary pain management strategies and clinical guidelines to reinforce beliefs about endocrine therapy.
Abstract
Purpose: Aromatase inhibitors (AIs) are widely prescribed for postmenopausal women with breast cancer and are known to cause musculoskeletal pain. This study aimed to identify factors associated with AI continuation intention among breast cancer survivors (BCS). Methods: A cross-sectional survey was conducted on 123 BCS (stages I–III), who had been taking AIs for at least 6 weeks. Participants were recruited from a cancer center in Goyang, Korea, from September to November 2019. Descriptive statistics, Welch analysis of variance, Pearson correlation coefficients, and simple linear regression were used for the analysis. Results: Beliefs about endocrine therapy was a significant predictor of AI continuation intention (β=.66, p<.001). The majority of participants (87.0%) reported experiencing musculoskeletal pain since taking AIs and the score for the worst pain severity within 24 hours was 5.08±2.80 out of 10. Musculoskeletal pain, however, was not associated with AI continuation intention. Fear of cancer recurrence (FCR) was clinically significant (≥13) for 74.0% of the respondents (mean, 17.62±7.14). Musculoskeletal pain severity and pain interference were significantly associated with FCR (r=.21, p<.05; r=.35, p<.01, respectively). Pain interference was significantly associated with beliefs about endocrine therapy (r=–.18, p<.05). Conclusion: AI continuation intention can be modified by reinforcing patients’ beliefs about endocrine therapy. Musculoskeletal pain may have a negative effect on beliefs about endocrine therapy and increase FCR among BCS. Thus, awareness of musculoskeletal pain during AI therapy should be raised and further research is required to develop multidisciplinary pain management strategies and clinical guidelines to reinforce beliefs about endocrine therapy.
참고문헌 (29)
- Gabrielle Emanuel, "Endocrine therapy in the years following a diagnosis of breast cancer: A proof of concept study using the primary care prescription database linked to cancer registration data", Cancer Epidemiology, 61, pp.185~189 (2019), Elsevier BV[DOI]
- Peng Xing, "Impact of persistence on survival of patients with breast cancer treated with endocrine therapy in Northeast China: a prospective study", Oncotarget, 8(60), pp.102499~102510 (2017), Impact Journals, LLC[DOI]
- Louise L. Beryl, "Mapping the Decision-Making Process for Adjuvant Endocrine Therapy for Breast Cancer", Medical Decision Making, 37(1), pp.79~90 (2017), SAGE Publications[DOI]
- Leah K. Lambert, "Understanding adjuvant endocrine therapy persistence in breast Cancer survivors", BMC Cancer, 18(1) (2018), Springer Science and Business Media LLC[DOI]
- Arden L. Corter, "Predicting nonadherence to adjuvant endocrine therapy in women with early stage breast cancer", Psycho-Oncology, 27(9), pp.2096~2103 (2018), Wiley[DOI]
- Amir H. Pakpour, "Intention and planning predicting medication adherence following coronary artery bypass graft surgery", Journal of Psychosomatic Research, 77(4), pp.287~295 (2014), Elsevier BV[DOI]
- Kannie Chim, "Joint pain severity predicts premature discontinuation of aromatase inhibitors in breast cancer survivors", BMC Cancer, 13(1) (2013), Springer Science and Business Media LLC[DOI]
- Janine M. Lombard, "Aromatase inhibitor induced musculoskeletal syndrome: a significant problem with limited treatment options", Supportive Care in Cancer, 24(5), pp.2139~2146 (2016), Springer Science and Business Media LLC[DOI]
- Jin Young Park, "Aromatase inhibitor-associated musculoskeletal symptoms: incidence and associated factors", Annals of Surgical Treatment and Research, 85(5), pp.205~211 (2013), 대한외과학회
- Tae-Hun Kim, "Therapeutic options for aromatase inhibitor-associated arthralgia in breast cancer survivors: A systematic review of systematic reviews, evidence mapping, and network meta-analysis", Maturitas, 118, pp.29~37 (2018), Elsevier BV[DOI]
- Caitriona Cahir, "Women’s experiences of hormonal therapy for breast cancer: exploring influences on medication-taking behaviour", Supportive Care in Cancer, 23(11), pp.3115~3130 (2015), Springer Science and Business Media LLC[DOI]
- Joo Yun Lee, "Relationships between determinants of adjuvant endocrine therapy adherence in breast cancer", BMC Women's Health, 18(1) (2018), Springer Science and Business Media LLC[DOI]
- Daniel L. Hall, "Fear of recurrence or progression as a link between somatic symptoms and perceived stress among cancer survivors", Supportive Care in Cancer, 25(5), pp.1401~1407 (2017), Springer Science and Business Media LLC[DOI]
- Clémentine Lopez, "Relations between arthralgia and fear of recurrence: results of a cross-sectional study of breast cancer patients treated with adjuvant aromatase inhibitors therapy", Supportive Care in Cancer, 23(12), pp.3581~3588 (2015), Springer Science and Business Media LLC[DOI]
- Teresa M. Salgado, "Identifying socio-demographic and clinical characteristics associated with medication beliefs about aromatase inhibitors among postmenopausal women with breast cancer", Breast Cancer Research and Treatment, 163(2), pp.311~319 (2017), Springer Science and Business Media LLC[DOI]
- Liana D. Castel, "Time course of arthralgia among women initiating aromatase inhibitor therapy and a postmenopausal comparison group in a prospective cohort", Cancer, 119(13), pp.2375~2382 (2013), Wiley[DOI]
- 이연희, "암 환자의 경구용 항암제 복용이행 영향요인", Asian Oncology Nursing, 13(4), pp.201~209 (2013), 대한종양간호학회
- Kunal C. Kadakia, "Patient-Reported Outcomes and Early Discontinuation in Aromatase Inhibitor-Treated Postmenopausal Women With Early Stage Breast Cancer", The Oncologist, 21(5), pp.539~546 (2016), Oxford University Press (OUP)[DOI]
- Young Ho Yun, "Development of a Cancer Pain Assessment Tool in Korea: A Validation Study of a Korean Version of the Brief Pain Inventory", Oncology, 66(6), pp.439~444 (2004), S. Karger AG[DOI]
- Cleeland CS, "Pain assessment : global use of the Brief Pain Inventory", Ann Acad Med Singap, 23(2), pp.129~138 (1994)
- Sébastien Simard, "Screening and comorbidity of clinical levels of fear of cancer recurrence", Journal of Cancer Survivorship, 9(3), pp.481~491 (2015), Springer Science and Business Media LLC[DOI]
- 신진영, "Validation Study for the Korean Version of Fear of Cancer Recurrence Inventory", Journal of Korean Medical Science, 32(11), pp.1792~1799 (2017), 대한의학회
- Sébastien Simard, "Fear of Cancer Recurrence Inventory: development and initial validation of a multidimensional measure of fear of cancer recurrence", Supportive Care in Cancer, 17(3), pp.241~251 (2009), Springer Science and Business Media LLC[DOI]
- Kim SH, "Development of an adjuvant endocrine therapy beliefs scale for breast cancer survivors", pp.2019
- Hye-Young Shim, "Physical activity status by pain severity in patients with knee osteoarthritis: a nationwide study in Korea", BMC Musculoskeletal Disorders, 19(1) (2018), Springer Science and Business Media LLC[DOI]
- Cleeland CS, "The brief pain inventory user guide", MD Anderson Cancer Center, ~ (2009)
- Sarah R. Heisig, "What do women with breast cancer expect from their treatment? Correlates of negative treatment expectations about endocrine therapy", Psycho-Oncology, 25(12), pp.1485~1492 (2016), Wiley[DOI]
- Amilie Boonstra, "Arthralgia During Aromatase Inhibitor Treatment in Early Breast Cancer Patients", Cancer Nursing, 36(1), pp.52~59 (2013), Ovid Technologies (Wolters Kluwer Health)[DOI]
- Alejandra Hurtado-de-Mendoza, "Providers’ perspectives on adherence to hormonal therapy in breast cancer survivors. Is there a role for the digital health feedback system?", Health and Technology, 9(2), pp.175~184 (2019), Springer Science and Business Media LLC[DOI]